| abstract |
The present invention concerns a pharmaceutical product to induce endogenous exacerbated release of gut hormones, pyy and glp1, with therapeutic effect on obesity and type 2 diabetes mellitus. In tablets form, suitable dosage forms such as pills capable of disintegration from a certain range of Ph or specific Ph range between 6.0 and 7.0, so that the undigested or partially hydrolyzed content is released in the distal jejunum and preferably in the ileum/proximal colon. And by contact with macro-nutrient molecules, or their hydrolyzed fragments, such cells suffer intense amplified stimulus and secrete the said hormones, released at rates that are therapeutics for obesity of any degree and also for type II diabetes; mimicking that produced and performed in bariatric and metabolic surgeries by a noninvasive method. |